Junne Kamihara, M.D., Ph.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Ribonuclease III | 11 | 2025 | 271 | 1.930 |
Why?
|
DEAD-box RNA Helicases | 11 | 2025 | 385 | 1.790 |
Why?
|
Germ-Line Mutation | 9 | 2024 | 1887 | 1.540 |
Why?
|
Neuroblastoma | 3 | 2024 | 1266 | 1.130 |
Why?
|
Pulmonary Blastoma | 5 | 2024 | 43 | 1.110 |
Why?
|
Neoplastic Syndromes, Hereditary | 4 | 2024 | 249 | 1.070 |
Why?
|
Paraganglioma | 3 | 2022 | 143 | 0.990 |
Why?
|
Retinoblastoma | 2 | 2017 | 321 | 0.910 |
Why?
|
Fumarate Hydratase | 2 | 2021 | 55 | 0.900 |
Why?
|
Genetic Predisposition to Disease | 14 | 2025 | 18068 | 0.840 |
Why?
|
DNA Mismatch Repair | 2 | 2022 | 432 | 0.810 |
Why?
|
Adrenal Gland Neoplasms | 3 | 2022 | 735 | 0.750 |
Why?
|
Indenes | 1 | 2021 | 59 | 0.730 |
Why?
|
Polycythemia | 1 | 2021 | 124 | 0.720 |
Why?
|
Colorectal Neoplasms, Hereditary Nonpolyposis | 1 | 2022 | 388 | 0.610 |
Why?
|
Central Nervous System Neoplasms | 3 | 2023 | 930 | 0.610 |
Why?
|
Sarcoma | 4 | 2024 | 1806 | 0.600 |
Why?
|
Li-Fraumeni Syndrome | 2 | 2017 | 117 | 0.560 |
Why?
|
Pinealoma | 1 | 2017 | 52 | 0.560 |
Why?
|
Retinoblastoma Binding Proteins | 1 | 2017 | 101 | 0.550 |
Why?
|
Ikaros Transcription Factor | 1 | 2018 | 233 | 0.540 |
Why?
|
Hamartoma Syndrome, Multiple | 3 | 2025 | 115 | 0.520 |
Why?
|
Human Development | 1 | 2016 | 122 | 0.500 |
Why?
|
Basic Helix-Loop-Helix Transcription Factors | 1 | 2021 | 1143 | 0.500 |
Why?
|
Registries | 6 | 2024 | 8384 | 0.430 |
Why?
|
Precursor Cell Lymphoblastic Leukemia-Lymphoma | 2 | 2018 | 1560 | 0.390 |
Why?
|
Neoplasms | 9 | 2025 | 22389 | 0.380 |
Why?
|
Thyroid Neoplasms | 2 | 2022 | 2360 | 0.380 |
Why?
|
Neoplasms, Germ Cell and Embryonal | 1 | 2016 | 496 | 0.370 |
Why?
|
Germ Cells | 4 | 2023 | 644 | 0.340 |
Why?
|
Child | 27 | 2025 | 80960 | 0.310 |
Why?
|
Sertoli-Leydig Cell Tumor | 2 | 2024 | 21 | 0.290 |
Why?
|
Ubiquitin-Protein Ligases | 1 | 2017 | 1902 | 0.290 |
Why?
|
Pheochromocytoma | 2 | 2022 | 328 | 0.290 |
Why?
|
PTEN Phosphohydrolase | 3 | 2025 | 1120 | 0.280 |
Why?
|
Syndrome | 3 | 2022 | 3274 | 0.280 |
Why?
|
Brain Neoplasms | 3 | 2024 | 9213 | 0.280 |
Why?
|
Attitude to Health | 1 | 2015 | 2025 | 0.260 |
Why?
|
Genetic Testing | 4 | 2024 | 3591 | 0.260 |
Why?
|
Tumor Suppressor Protein p53 | 1 | 2014 | 2960 | 0.220 |
Why?
|
Chondroitinsulfatases | 1 | 2023 | 16 | 0.220 |
Why?
|
Kidney Neoplasms | 4 | 2024 | 4300 | 0.220 |
Why?
|
Myofibromatosis | 1 | 2023 | 27 | 0.210 |
Why?
|
Child, Preschool | 13 | 2024 | 42683 | 0.210 |
Why?
|
Parents | 2 | 2023 | 3597 | 0.200 |
Why?
|
MutS Homolog 2 Protein | 1 | 2022 | 200 | 0.200 |
Why?
|
Normetanephrine | 1 | 2021 | 25 | 0.200 |
Why?
|
Homeodomain Proteins | 2 | 2024 | 2431 | 0.190 |
Why?
|
Chromogranins | 1 | 2021 | 160 | 0.180 |
Why?
|
Adolescent | 16 | 2025 | 89244 | 0.170 |
Why?
|
Adenomatous Polyposis Coli | 1 | 2022 | 219 | 0.170 |
Why?
|
Cadherins | 1 | 2024 | 906 | 0.170 |
Why?
|
Humans | 44 | 2025 | 768970 | 0.170 |
Why?
|
DNA Repair Enzymes | 1 | 2021 | 346 | 0.160 |
Why?
|
Adrenal Glands | 1 | 2021 | 557 | 0.160 |
Why?
|
Ovarian Neoplasms | 3 | 2024 | 4919 | 0.150 |
Why?
|
Multiple Endocrine Neoplasia | 1 | 2017 | 25 | 0.150 |
Why?
|
Thyroid Diseases | 1 | 2021 | 385 | 0.140 |
Why?
|
Rare Diseases | 1 | 2023 | 631 | 0.140 |
Why?
|
Basal Cell Nevus Syndrome | 1 | 2017 | 38 | 0.140 |
Why?
|
Leiomyomatosis | 1 | 2017 | 69 | 0.140 |
Why?
|
Jaw Neoplasms | 1 | 2017 | 71 | 0.140 |
Why?
|
Pedigree | 1 | 2024 | 4545 | 0.140 |
Why?
|
Tuberous Sclerosis | 1 | 2025 | 1042 | 0.140 |
Why?
|
BRCA2 Protein | 2 | 2023 | 803 | 0.130 |
Why?
|
Transcription Factors | 3 | 2024 | 12174 | 0.130 |
Why?
|
von Hippel-Lindau Disease | 1 | 2017 | 154 | 0.130 |
Why?
|
Hyperparathyroidism | 1 | 2017 | 339 | 0.130 |
Why?
|
Fibroma | 1 | 2017 | 199 | 0.130 |
Why?
|
Proto-Oncogene Proteins c-ret | 1 | 2017 | 228 | 0.120 |
Why?
|
Rhabdoid Tumor | 1 | 2017 | 211 | 0.120 |
Why?
|
Infant | 7 | 2024 | 36556 | 0.120 |
Why?
|
Genetic Variation | 2 | 2021 | 6611 | 0.120 |
Why?
|
Thyroid Nodule | 1 | 2022 | 767 | 0.120 |
Why?
|
Stomach Neoplasms | 1 | 2024 | 1483 | 0.110 |
Why?
|
Antigens, CD | 1 | 2024 | 4032 | 0.110 |
Why?
|
Receptor Protein-Tyrosine Kinases | 2 | 2017 | 1629 | 0.110 |
Why?
|
Wilms Tumor | 1 | 2016 | 378 | 0.110 |
Why?
|
Early Detection of Cancer | 4 | 2021 | 3238 | 0.110 |
Why?
|
Female | 18 | 2024 | 397515 | 0.110 |
Why?
|
Neoplasms, Multiple Primary | 1 | 2016 | 592 | 0.100 |
Why?
|
DNA Helicases | 1 | 2017 | 854 | 0.100 |
Why?
|
Male | 15 | 2024 | 365203 | 0.090 |
Why?
|
Neuromyelitis Optica | 1 | 2014 | 266 | 0.090 |
Why?
|
Genetic Counseling | 1 | 2014 | 634 | 0.090 |
Why?
|
Genotype | 3 | 2022 | 13048 | 0.090 |
Why?
|
Lung Neoplasms | 3 | 2024 | 13594 | 0.080 |
Why?
|
High-Throughput Nucleotide Sequencing | 1 | 2022 | 3671 | 0.080 |
Why?
|
Proto-Oncogene Proteins | 2 | 2017 | 4528 | 0.080 |
Why?
|
Adult | 10 | 2024 | 223851 | 0.080 |
Why?
|
Genetic Association Studies | 1 | 2018 | 2748 | 0.080 |
Why?
|
Uterine Neoplasms | 1 | 2017 | 1424 | 0.080 |
Why?
|
Social Class | 1 | 2016 | 2009 | 0.070 |
Why?
|
Interviews as Topic | 1 | 2015 | 2744 | 0.070 |
Why?
|
Tumor Suppressor Proteins | 1 | 2017 | 2812 | 0.070 |
Why?
|
Glioma | 1 | 2022 | 3532 | 0.070 |
Why?
|
Practice Guidelines as Topic | 1 | 2024 | 7460 | 0.070 |
Why?
|
Prognosis | 4 | 2024 | 30046 | 0.070 |
Why?
|
Adenoma | 1 | 2017 | 2163 | 0.070 |
Why?
|
Residence Characteristics | 1 | 2016 | 2121 | 0.070 |
Why?
|
Bone Marrow Transplantation | 1 | 2014 | 2709 | 0.070 |
Why?
|
Genome-Wide Association Study | 1 | 2024 | 12801 | 0.060 |
Why?
|
Poverty | 1 | 2016 | 2720 | 0.060 |
Why?
|
Infant, Newborn | 3 | 2023 | 26428 | 0.060 |
Why?
|
Developing Countries | 1 | 2016 | 2911 | 0.060 |
Why?
|
Amino Acid Transport System y+L | 1 | 2023 | 17 | 0.050 |
Why?
|
Phenotype | 1 | 2021 | 16731 | 0.050 |
Why?
|
Magnetic Resonance Imaging | 3 | 2021 | 36854 | 0.050 |
Why?
|
Mutation | 4 | 2022 | 30266 | 0.050 |
Why?
|
Nuclear Proteins | 1 | 2017 | 5804 | 0.050 |
Why?
|
Sex Cord-Gonadal Stromal Tumors | 1 | 2024 | 118 | 0.050 |
Why?
|
Receptor, Platelet-Derived Growth Factor beta | 1 | 2023 | 183 | 0.050 |
Why?
|
Antiporters | 1 | 2023 | 276 | 0.050 |
Why?
|
Young Adult | 6 | 2024 | 60131 | 0.050 |
Why?
|
3-Iodobenzylguanidine | 1 | 2022 | 115 | 0.050 |
Why?
|
Monosaccharide Transport Proteins | 1 | 2023 | 437 | 0.050 |
Why?
|
Colorectal Neoplasms | 1 | 2021 | 6982 | 0.050 |
Why?
|
Loss of Heterozygosity | 1 | 2023 | 663 | 0.050 |
Why?
|
Receptors, Growth Factor | 1 | 2001 | 326 | 0.040 |
Why?
|
Gastrectomy | 1 | 2024 | 693 | 0.040 |
Why?
|
Risk Factors | 5 | 2021 | 74976 | 0.040 |
Why?
|
Survival Rate | 2 | 2024 | 12873 | 0.040 |
Why?
|
Retrospective Studies | 3 | 2022 | 81903 | 0.040 |
Why?
|
Signal Transduction | 1 | 2021 | 23653 | 0.040 |
Why?
|
Neonatal Screening | 1 | 2023 | 619 | 0.040 |
Why?
|
Incidence | 1 | 2016 | 21547 | 0.040 |
Why?
|
Radionuclide Imaging | 1 | 2022 | 1998 | 0.040 |
Why?
|
Multiple Endocrine Neoplasia Type 2b | 1 | 2017 | 10 | 0.040 |
Why?
|
Testicular Neoplasms | 1 | 2024 | 808 | 0.040 |
Why?
|
Skin Neoplasms | 1 | 2017 | 5864 | 0.040 |
Why?
|
BRCA1 Protein | 1 | 2023 | 1156 | 0.030 |
Why?
|
Genomics | 2 | 2023 | 5928 | 0.030 |
Why?
|
Prospective Studies | 4 | 2023 | 54962 | 0.030 |
Why?
|
Middle Aged | 4 | 2024 | 223737 | 0.030 |
Why?
|
Penetrance | 1 | 2018 | 386 | 0.030 |
Why?
|
Doxorubicin | 1 | 2022 | 2234 | 0.030 |
Why?
|
Inheritance Patterns | 1 | 2018 | 344 | 0.030 |
Why?
|
Chemotherapy, Adjuvant | 1 | 2024 | 3554 | 0.030 |
Why?
|
Mass Screening | 2 | 2022 | 5457 | 0.030 |
Why?
|
Fanconi Anemia | 1 | 2016 | 327 | 0.030 |
Why?
|
Protein Structure, Tertiary | 1 | 2001 | 3775 | 0.030 |
Why?
|
Plasmapheresis | 1 | 2014 | 206 | 0.030 |
Why?
|
Fluorodeoxyglucose F18 | 1 | 2022 | 2056 | 0.030 |
Why?
|
Extracellular Matrix | 1 | 2001 | 1739 | 0.030 |
Why?
|
Transfection | 1 | 2001 | 5763 | 0.030 |
Why?
|
Chromatin Assembly and Disassembly | 1 | 2017 | 633 | 0.030 |
Why?
|
Collagen | 1 | 2001 | 2646 | 0.030 |
Why?
|
Prevalence | 2 | 2021 | 15879 | 0.020 |
Why?
|
DNA Damage | 1 | 2022 | 2472 | 0.020 |
Why?
|
Radiopharmaceuticals | 1 | 2022 | 2734 | 0.020 |
Why?
|
Follow-Up Studies | 2 | 2024 | 39394 | 0.020 |
Why?
|
Optic Nerve | 1 | 2014 | 571 | 0.020 |
Why?
|
Molecular Targeted Therapy | 1 | 2022 | 2830 | 0.020 |
Why?
|
Neovascularization, Pathologic | 1 | 2001 | 2634 | 0.020 |
Why?
|
Decision Making | 1 | 2024 | 3953 | 0.020 |
Why?
|
Population Surveillance | 1 | 2021 | 2597 | 0.020 |
Why?
|
Prenatal Diagnosis | 1 | 2018 | 1275 | 0.020 |
Why?
|
Cell Movement | 1 | 2001 | 5216 | 0.020 |
Why?
|
Endothelium, Vascular | 1 | 2001 | 4428 | 0.020 |
Why?
|
Peptide Fragments | 1 | 2001 | 5151 | 0.020 |
Why?
|
Bacterial Proteins | 1 | 2001 | 3840 | 0.020 |
Why?
|
Ultrasonography | 1 | 2021 | 6002 | 0.020 |
Why?
|
Disease Management | 1 | 2018 | 2537 | 0.020 |
Why?
|
Aged | 3 | 2024 | 171786 | 0.020 |
Why?
|
Repressor Proteins | 1 | 2017 | 2986 | 0.020 |
Why?
|
Spinal Cord | 1 | 2014 | 1813 | 0.020 |
Why?
|
Positron-Emission Tomography | 1 | 2022 | 6673 | 0.020 |
Why?
|
Neoplasm Proteins | 1 | 2017 | 3608 | 0.020 |
Why?
|
Combined Modality Therapy | 1 | 2016 | 8559 | 0.010 |
Why?
|
Pilot Projects | 1 | 2017 | 8748 | 0.010 |
Why?
|
Disease Progression | 1 | 2021 | 13674 | 0.010 |
Why?
|
United States | 2 | 2021 | 73186 | 0.010 |
Why?
|
Collagen Type XVIII | 1 | 2001 | 52 | 0.010 |
Why?
|
Cross-Sectional Studies | 1 | 2022 | 26395 | 0.010 |
Why?
|
Endostatins | 1 | 2001 | 168 | 0.010 |
Why?
|
rac GTP-Binding Proteins | 1 | 2001 | 163 | 0.010 |
Why?
|
Cytotoxins | 1 | 2001 | 154 | 0.010 |
Why?
|
cdc42 GTP-Binding Protein | 1 | 2001 | 188 | 0.010 |
Why?
|
rho GTP-Binding Proteins | 1 | 2001 | 279 | 0.010 |
Why?
|
Dimerization | 1 | 2001 | 886 | 0.010 |
Why?
|
Diagnosis, Differential | 1 | 2014 | 13021 | 0.010 |
Why?
|
Evaluation Studies as Topic | 1 | 2001 | 1629 | 0.010 |
Why?
|
Tomography, X-Ray Computed | 1 | 2022 | 20776 | 0.010 |
Why?
|
Leukemia, Myeloid, Acute | 1 | 2014 | 3626 | 0.010 |
Why?
|
Cohort Studies | 1 | 2021 | 41808 | 0.010 |
Why?
|
Aged, 80 and over | 1 | 2023 | 59739 | 0.010 |
Why?
|
Vascular Endothelial Growth Factor Receptor-1 | 1 | 2001 | 560 | 0.010 |
Why?
|
Receptors, Vascular Endothelial Growth Factor | 1 | 2001 | 664 | 0.010 |
Why?
|
Morphogenesis | 1 | 2001 | 747 | 0.010 |
Why?
|
Algorithms | 1 | 2018 | 14201 | 0.010 |
Why?
|
Adenoviridae | 1 | 2001 | 1095 | 0.010 |
Why?
|
Risk Assessment | 1 | 2018 | 24333 | 0.010 |
Why?
|
Mitogen-Activated Protein Kinases | 1 | 2001 | 1246 | 0.010 |
Why?
|
Bacterial Toxins | 1 | 2001 | 922 | 0.010 |
Why?
|
Cell Division | 1 | 2001 | 4478 | 0.010 |
Why?
|
Blotting, Western | 1 | 2001 | 5033 | 0.010 |
Why?
|
Tumor Cells, Cultured | 1 | 2001 | 6131 | 0.010 |
Why?
|
Recombinant Fusion Proteins | 1 | 2001 | 3744 | 0.010 |
Why?
|
Angiogenesis Inhibitors | 1 | 2001 | 2059 | 0.010 |
Why?
|
Amino Acid Sequence | 1 | 2001 | 13427 | 0.010 |
Why?
|
Molecular Sequence Data | 1 | 2001 | 17629 | 0.000 |
Why?
|
Cells, Cultured | 1 | 2001 | 19023 | 0.000 |
Why?
|
Mice | 2 | 2001 | 82072 | 0.000 |
Why?
|
Animals | 2 | 2001 | 169335 | 0.000 |
Why?
|